The DOI matches its Crossref record.
HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Abstract
In the last decade, the molecular chaperone HSP90 has emerged as an important target in cancer therapeutics and has subsequently become the focus of several drug discovery and development efforts. The first-in-class HSP90 inhibitor 17-AAG entered into Phase I clinical trial in 1999. Today 13 HSP90 inhibitors representing multiple drug classes, with different modes of action, are undergoing clinical evaluation. The present review will highlight the involvement of HSP90 in regulating and maintaining the transformed phenotype, provide an overview on current HSP90 inhibitors and further update on the most relevant patents which have recently appeared in the literature. Keywords: Cancer therapeutics, cell surface, chaperoning, drug discovery, HSP90, signal transduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, to date, there are no clinically approved HSP90 inhibitors, as most trials have been associated with limited efficacy and significant toxicity”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [11]
In the citing paper
“presumably because HSP90 inhibition promotes the degradation of different substrates in different tissues and rapidly induces stress responses that may mediate resistance.11”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [11]
Citations
Cited by
Sorted by citations
Items 201–222 of 222
Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy
Chatterjee, S., & Burns, T. F. (2019) · Heat shock proteins · doi:10.1007/978-3-030-03952-3_19
The Role of Heat Shock Protein -90 (HSP-90) in Inflammatory Disorders
Bhattacharjee, C., & Deb, L. (2020) · Current Chemical Biology · doi:10.2174/2212796814666200122114833
HSP90 inhibition attenuated isoflurane-induced neurotoxicity in rat and human neuroglioma cellsPreprint
Zhang, C., Chen, X., Zhang, W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2581339/v1
Identification of circRNA-miRNA-mRNA Network Regulated by Hsp90 in Human Melanoma A375 Cells
Fu, Q., Gao, H., Liu, K., Su, J., Zhang, J., Guo, X., & Yang, F. Y. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230609145247
Unravelling the p53 misfolding by chaperones in cancer
Jan, N., Jan, A., Sofi, S., & Mir, M. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.011
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253759
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253756
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253762
Wang, Q., Liu, P., Wen, Y., Li, K., Bi, B., Li, B., Qiu, M., Zhang, S., Li, Y., Li, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23520176
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253774
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253768
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253780
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253765
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253783
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253747
Marx, C., Schaarschmidt, M. U., Kirkpatrick, J., Marx-Blümel, L., Halilovic, M., Westermann, M., Hoelzer, D., Meyer, F. B., Geng, Y., Buder, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14253777
Etude du mécanisme d'action de l'interféron alpha dans les néoplasmes myéloprolifératifs classiques
Mosca, M. (2018) · theses.fr (ABES) · doi:10.70675/55d9ced7z385bz4e31zb710z8c57b151cd29
Vanlaeys, A. (2018) · theses.fr (ABES) · doi:10.70675/38e3152fzf834z4cfaz934azabfae8a37fdf
Mathieu, C. (2021) · theses.fr (ABES) · doi:10.70675/22a753dcze788z44dfz8a6az8a41b201d605
Du, J., 牛静, Shuping, Z., & Wang, S. (2026) · Journal of International Medical Research · doi:10.1177/03000605261440829
Heidari, N., Pishraft-sabet, H., Gol, R., Najari, D., Eghbali, S., Heidari, A., & Mahmoudi, H. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02265-8 · Cited by 1
“Hsp90 inhibitors were first entered into a phase I clinical trial in 1999 (Sidera and Patsavoudi 2014 ).”
Metadata
- Authors
- Sidera, K., & Patsavoudi, E.
- Affiliations
- Pasteur Hellenic Institute (GR)
- Venue
- Recent Patents on Anti-Cancer Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-12-13
- Volume
- 9
- Issue
- 1
- Pages
- 1-20
- ISSN
- 1574-8928 (ISSN-L)
- OpenAlex
- W4245469960
- Cited by
- 222
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 17 · 2022: 14 · 2021: 28 · 2020: 21 · 2019: 31 · 2018: 18 · 2017: 19 · 2016: 28 · 2015: 19 · 2014: 8 · 2013: 1
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- Hsp90 inhibitors, HSP90, molecular chaperones, cancer therapeutics, 17-AAG, drug discovery, clinical trials, patents, transformed phenotype, signal transduction, cell surface
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
